PubRank

Weichung Shih

Author PubWeight™ 31.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008 5.66
2 Outcomes of localized prostate cancer following conservative management. JAMA 2009 5.57
3 Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009 2.85
4 Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol 2011 2.69
5 Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011 2.53
6 Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 2013 2.10
7 Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005 1.66
8 Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer? Eur Urol 2012 1.55
9 A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genome Res 2005 1.21
10 δ- and γ-tocopherols, but not α-tocopherol, inhibit colon carcinogenesis in azoxymethane-treated F344 rats. Cancer Prev Res (Phila) 2012 0.98
11 Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res 2003 0.95
12 Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit 2012 0.85
13 A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res 2002 0.84
14 Failure to report financial disclosure information. JAMA 2009 0.83
15 Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs 2008 0.82
16 Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last? J Urol 2012 0.81
17 A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. Med Sci Monit 2003 0.80